FOR IMMEDIATE RELEASE

Media Contact:
Media@SKLifeScienceInc.com

SK life science to present data on cenobamate, an investigational antiepileptic compound, at ASCPT 2018 Annual Meeting

Fair Lawn, New Jersey, March 6, 2018 – SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative biopharmaceutical company focused on developing and bringing to market treatments for disorders of the central nervous system (CNS), today announced that it will present pharmacokinetic and drug interaction data from studies of its novel, investigational compound, cenobamate (YKP3089), which is being investigated for the potential treatment of adults with partial-onset seizures, at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting (ASCPT), March 21-24, in Orlando, Fla.

SK life science will highlight results from two studies in the following abstracts:

• Poster Session 1, Thursday, March 22, 5 to 6:30 p.m. ET.
  o Abstract Number: PI-153 - Pharmacokinetics of cenobamate (YKP3089): Results from Single and Multiple Oral Rising-Dose Studies in Healthy Subjects.

• Poster Session 2, Friday, March 23, 7 to 8:30 a.m. ET.
  o Abstract Number: PII-135 - Drug-Drug Interactions between cenobamate and Other Antiepileptic Drugs: Results from Phase I Studies with Carbamazepine, Phenobarbital, Phenytoin, and Divalproex Sodium.

“These abstracts mark the first PK data shared at a major medical conference on our investigational compound cenobamate, which we are studying as a potential treatment for adults with epilepsy, a community who faces a significant unmet medical need,” said Marc Kamin, M.D., chief medical officer at SK life science.

Both abstracts have been published in the March supplement of Clinical Pharmacology & Therapeutics.

About SK life science
SK life science is a subsidiary of SK biopharmaceuticals, focused on developing and bringing treatments for disorders of the central nervous system (CNS) to market. Both are a part of the global conglomerate SK Group, the second largest company in Korea. SK life science is growing quickly in the U.S., with headquarters in Fair Lawn, New Jersey.

SK life science has a pipeline of six products in development for the treatment of CNS disorders including epilepsy, sleep disorder and attention deficit hyperactivity disorder, among others. The company’s lead product is cenobamate, an investigational compound that is being studied as a potential treatment option for patients with epilepsy.
For more information, visit SK life science’s website at www.SKLifeScienceInc.com.

About SK biopharmaceuticals
SK biopharmaceuticals Co., Ltd. is a part of the global conglomerate SK Group, the second largest company in Korea. SK biopharmaceuticals (global headquarters) is responsible for the development of innovative next-generation drugs within SK Group.

For more information, visit SK biopharmaceuticals’ website at www.skbp.com.

###